{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:05Z","timestamp":1791903305596,"version":"4.3.4"},"reference-count":36,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Follow-up of potential germ line variants revealed by diagnostic targeted sequencing (TS) for myelodysplastic syndromes (MDS) has been proposed by clinical guidelines. However, their feasibility and clinical yield in routine MDS practice remain uncertain. We evaluated the real-world applicability of systematic germ line follow-up in an unselected cohort of 716 patients (median age, 74 years) evaluated for MDS. Their diagnostic TS data were analyzed to identify variants in CEBPA, DDX41, ETV6, GATA2, and RUNX1 with a variant allele frequency of \u226535%. In total, 98 variants were identified in 87 (12.2%) patients. Germ line investigation was possible for 62 patients; for the remaining 25 without biobanked material, medical charts were reviewed. We identified pathogenic\/likely pathogenic (P\/LP) germ line variants in 19 patients (2.7%). Most P\/LP variants were found in DDX41 (73.7%), followed by 10.5%, 10.5%, and 5.3% in RUNX1, GATA2, and ETV6, respectively, with germ line conversion rates between 5.4% and 93.3%. Patients with P\/LP variants had a median age at diagnosis of 73 years, with male predominance (3.75:1). Most patients were diagnosed with MDS\u2013excess blasts-1 (MDS-EB1) or MDS-EB2 (68.4%) and had normal cytogenetics (95%). A review of medical charts in younger patients (aged &amp;lt;50 years) revealed germ line predisposition in other genes in an additional 5 patients, revisiting the prevalence of predisposition to 3.4% overall and to 16.7% in those aged &amp;lt;50 years. Our results show that systematic germ line follow-up after diagnostic TS succeeds in identifying predisposition in nearly 3% of patients at a typical adult MDS clinic. Germ line testing for genes not routinely assessed by diagnostic TS is required in younger patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019942","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:24:07Z","timestamp":1785457447000},"page":"6742-6753","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world investigation of germ line predisposition to myelodysplastic syndromes"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9745-723X","authenticated-orcid":false,"given":"Anna","family":"Tranberg","sequence":"first","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"},{"name":"2Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-0871","authenticated-orcid":false,"given":"Maria","family":"Creignou","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"},{"name":"3Center for Clinical Cancer Studies, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8399-1430","authenticated-orcid":false,"given":"Teresa","family":"Mortera Blanco","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2057-7187","authenticated-orcid":false,"given":"Elsa","family":"Bernard","sequence":"additional","affiliation":[{"name":"4UMR981, Gustave Roussy, Villejuif, France"},{"name":"5IHU PRISM National Precision Medicine Center in Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3745-503X","authenticated-orcid":false,"given":"Ann-Charlotte","family":"Bj\u00f6rklund","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Hillberg Widfeldt","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"},{"name":"2Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira","family":"Barbosa","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2074-2173","authenticated-orcid":false,"given":"Matilda","family":"Kjellander Kynning","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5719-7287","authenticated-orcid":false,"given":"David","family":"Cabrerizo Granados","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"},{"name":"6Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo\/Consejo Superior de Investigaciones Cient\u00edficas\/Universidad de Sevilla, Seville, Spain"},{"name":"7Department of Medical Physiology and Biophysics, University of Seville, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-3370","authenticated-orcid":false,"given":"Vanessa","family":"Lundin","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-7296","authenticated-orcid":false,"given":"Johanna","family":"Ungerstedt","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"},{"name":"8Department of Hematology, Link\u00f6ping University Hospital, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6583-3829","authenticated-orcid":false,"given":"Gabriele","family":"Todisco","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"},{"name":"9Department of Biomedical Sciences, Humanitas University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2002-0458","authenticated-orcid":false,"given":"Elli","family":"Papaemmanuil","sequence":"additional","affiliation":[{"name":"10Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7839-3743","authenticated-orcid":false,"given":"Eva","family":"Hellstr\u00f6m Lindberg","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"},{"name":"2Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8253-2507","authenticated-orcid":false,"given":"Bianca","family":"Tesi","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"},{"name":"11Clinical Genetics and Genomics, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"20","key":"2026101310413040200_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2026101310413040200_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026101310413040200_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2026101310413040200_bib4","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood.2022015790","article-title":"Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages","volume":"140","author":"Feurstein","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2026101310413040200_bib5","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/s41375-021-01137-0","article-title":"Germline variants drive myelodysplastic syndrome in young adults","volume":"35","author":"Feurstein","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"2026101310413040200_bib6","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2021011354","article-title":"Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML","volume":"139","author":"Yang","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026101310413040200_bib7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.2022019304","article-title":"Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity","volume":"142","author":"Molteni","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2026101310413040200_bib8","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1002\/hem3.112","article-title":"Prospective genetic germline evaluation in a consecutive group of adult patients aged &lt;60 years with myelodysplastic syndromes","volume":"8","author":"Attardi","year":"2024","journal-title":"HemaSphere"},{"issue":"6","key":"2026101310413040200_bib9","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1097\/HS9.0000000000000321","article-title":"Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, clinical management and follow-up","volume":"3","author":"Baliakas","year":"2019","journal-title":"HemaSphere"},{"issue":"2","key":"2026101310413040200_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","article-title":"NCCN Guidelines\u00ae insights: myelodysplastic syndromes, version 3.2022: featured updates to the NCCN guidelines","volume":"20","author":"Greenberg","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"2026101310413040200_bib11","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026101310413040200_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/bjh.18682","article-title":"Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar , NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)","volume":"201","author":"Clark","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"2026101310413040200_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.annonc.2022.12.003","article-title":"Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations","volume":"34","author":"Kuzbari","year":"2023","journal-title":"Ann Oncol"},{"key":"2026101310413040200_bib14","doi-asserted-by":"crossref","first-page":"4738660","DOI":"10.1155\/2023\/4738660","article-title":"Frequency and functional characterization of RUNX1 germline variants in myeloid neoplasms","volume":"2023","author":"Nitschke","year":"2023","journal-title":"Hum Mutat"},{"issue":"21","key":"2026101310413040200_bib15","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood.2019003357","article-title":"High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML","volume":"135","author":"Simon","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2026101310413040200_bib16","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.3324\/haematol.2023.282867","article-title":"Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms","volume":"108","author":"Badar","year":"2023","journal-title":"Haematologica"},{"issue":"23","key":"2026101310413040200_bib17","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1182\/bloodadvances.2023011389","article-title":"The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing","volume":"7","author":"Maierhofer","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"2026101310413040200_bib18","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1158\/1078-0432.CCR-24-4251","article-title":"Validation of guidelines for genetic investigation of myeloid neoplasms with germline predisposition: results from a prospective cohort study","volume":"31","author":"Tesi","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026101310413040200_bib19","doi-asserted-by":"crossref","first-page":"e2300518","DOI":"10.1200\/PO.23.00518","article-title":"Implementation of and systems-level barriers to guideline-driven germline genetic evaluation in the care of patients with myelodysplastic syndrome and acute myeloid leukemia","volume":"8","author":"Banaszak","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"2026101310413040200_bib20","doi-asserted-by":"crossref","first-page":"e70206","DOI":"10.1002\/jha2.70206","article-title":"Low rate of germline investigation for variants of suspected germline origin detected during the diagnostic work-up of myeloid neoplasms","volume":"6","author":"Al-Djaber","year":"2025","journal-title":"EJHaem"},{"issue":"7","key":"2026101310413040200_bib26","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"20","key":"2026101310413040200_bib35","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1158\/1078-0432.CCR-23-0538","article-title":"Integrated genomic and transcriptomic analysis improves disease classification and risk stratification of MDS with ring sideroblasts","volume":"29","author":"Todisco","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026101310413040200_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/joim.13790","article-title":"Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes","volume":"296","author":"Creignou","year":"2024","journal-title":"J Intern Med"},{"issue":"7","key":"2026101310413040200_bib23","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood.2021015135","article-title":"The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026101310413040200_bib21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/gcc.23184","article-title":"The clinical phenotype of germline RUNX1 mutations in relation to the accompanying somatic variants and RUNX1 isoform expression","volume":"62","author":"Cabrerizo Granados","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"key":"2026101310413040200_bib24","doi-asserted-by":"crossref","first-page":"34756","DOI":"10.1038\/srep34756","article-title":"Structural and functional analysis of DDX41: a bispecific immune receptor for DNA and cyclic dinucleotide","volume":"6","author":"Omura","year":"2016","journal-title":"Sci Rep"},{"issue":"23","key":"2026101310413040200_bib22","first-page":"2853","article-title":"The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia","volume":"141","author":"Hakkarainen","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026101310413040200_bib25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7326\/L24-0125","article-title":"Germline UBA1 variant with somatic amplification in a woman with inflammatory diseases and myelodysplastic syndrome","volume":"178","author":"Creignou","year":"2025","journal-title":"Ann Intern Med"},{"issue":"15","key":"2026101310413040200_bib27","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026101310413040200_bib28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/bloodadvances.2017013037","article-title":"Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies","volume":"2","author":"Drazer","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"2026101310413040200_bib29","doi-asserted-by":"crossref","first-page":"101037","DOI":"10.1016\/j.gim.2023.101037","article-title":"Sequential tumor molecular profiling identifies likely germline variants","volume":"26","author":"Kraft","year":"2024","journal-title":"Genet Med"},{"issue":"23","key":"2026101310413040200_bib30","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2024025023","article-title":"Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations","volume":"144","author":"Gutierrez-Rodrigues","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026101310413040200_bib31","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/bloodadvances.2019000901","article-title":"RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML","volume":"4","author":"Brown","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"2026101310413040200_bib32","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1182\/blood-2012-08-452763","article-title":"GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome","volume":"121","author":"Hsu","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2026101310413040200_bib33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jha2.1012","article-title":"Beyond myeloid neoplasms germline guidelines: validation of the thresholds criteria in the search of germline predisposition variants","volume":"5","author":"Mestre","year":"2024","journal-title":"EJHaem"},{"issue":"11","key":"2026101310413040200_bib34","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1007\/s00277-025-06699-y","article-title":"Evaluation of reference sample type for somatic variant calling in myeloid cancers","volume":"104","author":"Jakobsen","year":"2025","journal-title":"Ann Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6742\/2593668\/blooda_adv-2026-019942-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6742\/2593668\/blooda_adv-2026-019942-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:41:40Z","timestamp":1791902500000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6742\/569985\/Real-world-investigation-of-germ-line"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":36,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019942","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,10,1]]}}}